According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “
NASDAQ VCNX opened at $2.45 on Wednesday. The company has a quick ratio of 4.48, a current ratio of 4.48 and a debt-to-equity ratio of 0.05. Vaccinex has a one year low of $1.63 and a one year high of $9.56. The firm’s 50 day moving average price is $2.53.
Several hedge funds and other institutional investors have recently bought and sold shares of VCNX. Tacita Capital Inc bought a new stake in Vaccinex in the fourth quarter worth $28,000. Bank of New York Mellon Corp bought a new stake in Vaccinex in the first quarter worth $54,000. Virtu Financial LLC bought a new stake in Vaccinex in the first quarter worth $56,000. Institute for Wealth Management LLC. bought a new stake in Vaccinex in the first quarter worth $60,000. Finally, UBS Group AG bought a new stake in Vaccinex in the first quarter worth $86,000. Hedge funds and other institutional investors own 3.29% of the company’s stock.
Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.
Read More: Average Daily Trade Volume – ADTV
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.